Mostrando resultados por título "Breakthrough" en Industria de la Medicina y Salud

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

It is 1919 and Elizabeth Hughes, the 11-year-old daughter of America's most-distinguished jurist and politician, Charles Evans Hughes, has been diagnosed with juvenile diabetes. It is essentially a death sentence. The only accepted form of treatment - starvation - whittles her down to 45 pounds, skin and bones. Miles away, Canadian researchers Frederick Banting and Charles Best manage to identify and purify insulin from animal pancreases - a miracle soon marred by scientific jealousy, intense business competition, and fistfights.

At one time heart disease was a death sentence. By the middle of the 20th century, it was killing millions, and, as with the Black Death centuries before, physicians stood helpless. Visionaries, though, had begun to make strides earlier. On September 7, 1895, Ludwig Rehn successfully sutured the heart of a living man with a knife wound to the chest for the first time.

Welcome to "The Methylene Blue Revolution," your indispensable guide to one of the most groundbreaking innovations in modern healthcare. This book aims to educate, enlighten, and empower you with an in-depth understanding of Methylene Blue, a substance that has shown incredible promise in medical research and treatment strategies. If you've been grappling with healthcare woes and felt the pain of stagnation, this is the book that will provide you with actionable solutions.

Promising treatments now in more than 35,000 clinical trials could have dramatic impacts on cancer, autoimmune diseases, organ replacement, heart disease, and even aging itself. These treatments, which are saving the lives of patients in the trials, will soon be rolled to the medical community at large. The key to these breakthroughs is the use of living cells as medicine instead of traditional drugs. Research has found that our bodies are virtual treasure troves of adult cells that act as agents of remarkable healing and repair.

In Good Blood, best-selling writer Julian Guthrie tells the gripping tale of the race to cure a horrible affliction known as Rh disease that stalked families and caused a mother’s immune system to attack her own unborn child. The story is anchored by two very different men on two continents: Dr. John Gorman in New York, who would land on a brilliant yet contrarian idea, and the unassuming Australian whose almost magical blood - and his unyielding devotion to donating it - would save millions of lives.

Pandemics have afflicted human civilizations throughout history, yet these health crises have also led to progress in medicine and society that improved people’s lives. History shows that scientific innovation often proceeds from the collaboration of researchers across disciplines, nations, and institutions.

In mid-January 2020, scientists Ugur Sahin and Özlem Türeci learned of how a new virus that had emerged in Wuhan, China, was spreading. Recognising the threat at once, they dropped everything and committed themselves to developing a vaccine against the disease that would soon be known as COVID-19. No one believed it was possible. But by December, the revolutionary BioNTech-Pfizer mRNA inoculation became the first clinically approved COVID-19 vaccine. Soon it was being injected into the arms of millions, turning the tide on the deadliest pandemic in living memory.